New research indicates that people who discontinue popular weight-loss injections like semaglutide or tirzepatide tend to recover shed pounds far faster than those who end traditional diet and exercise regimens.
Findings released in a leading medical journal demonstrates that while overweight people can lose substantial amounts of their body weight while using the jabs, the mass is regained at an estimated rate of nearly a kilo each month after stopping.
"Users using such medications should be cognizant of the potential of rapid weight regain when the therapy ends," cautioned lead investigator Dr. Susan Jebb.
This pace of recovery suggests a reversion to pre-treatment mass within about one and a half years.
Weighing Approaches
The research, which looked at dozens of trials involving thousands of patients, compared the effects of GLP-1 agonists with other pills.
Researchers point out that people who lose weight through diet and exercise generally see a less rapid weight regain—approximately 0.1 kg a month—after stopping.
Understanding the Quick Rebound
Experts suggest the mechanism of the jabs explains the amplified regain.
These medications copy a natural hormone called GLP-1, which helps regulate feelings of fullness.
"Long-term administration of GLP-1 concentrations far above than the body's typical production might result in the body to produce less of its endogenous GLP-1, and could diminish responsiveness to its effects," noted Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this hormone supplement means hunger is unsuppressed, making excessive eating a significant risk."
A Chronic Condition?
Medical guidelines suggest the injections for people with obesity-related medical conditions, accompanied by recommended lifestyle changes.
Many experts argue that, considering the high risk of weight regain, the treatment might need to be long-term.
This view is reinforced by drug manufacturers, who note that the findings "underscore the long-term character of obesity," akin to managing conditions like high blood pressure.
Patient Experiences
Users who have come off the jabs describe a intense resurgence of appetite.
"I experienced a switch that goes on and you become extremely hungry," said a patient.
This challenge is compounded if individuals have not developed lasting dietary or behavioural modifications during treatment.
Widespread Interest
Survey data show that a significant number of people in the UK have tried these injections in the last 12 months, with interest being substantial.
- Adoption is higher among women than males.
- The 40s and 50s age group shows the highest usage rates.
- A large proportion obtain the medications through private healthcare rather than the NHS.
Finally, researchers stress that while the jabs are effective agents for shedding pounds, they are not a magic cure and long-term success relies on integrated lifestyle support.
